<DOC>
	<DOCNO>NCT00554983</DOCNO>
	<brief_summary>Efficacy Safety recombinant fold variant Bet v 1</brief_summary>
	<brief_title>Efficacy Safety From Recombinant Folding Variant Bet v 1</brief_title>
	<detailed_description />
	<criteria>Allergic rhinoconjunctivitis attributable birch pollen Positive SPT Positive EAST Positive specific provocation test Serious chronic diseases Other perennial allergy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>November 2013</verification_date>
	<keyword>Recombinant birch pollen allergy</keyword>
	<keyword>IgE-mediated allergic disease attribute birch pollen</keyword>
</DOC>